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Opioid receptors belong to the G protein coupled receptor family. They modulate brain function at all levels of 
neural integration and therefore impact on autonomous, sensory, emotional and cognitive processing. In vivo 
functional interaction between mu and delta opioid receptors are known to take place though it is still debated 
whether interactions occur at circuitry, cellular or molecular level. Also, the notion of receptor crosstalk via mu-
delta heteromers is well documented in vitro but in vivo evidence remains scarce. To identify neurons in which 
receptor interactions could take place, we designed a unique double mutant knock-in mouse line that expresses 
functional red-fluorescent mu receptors and green-fluorescent delta receptors. We mapped mu and delta 
receptor distribution and co-localization throughout the nervous system and created the first interactive brain 
atlas with concomitant mu-delta visualization at subcellular resolution (http://mordor.ics-mci.fr/). Mu and delta 
receptors co-localize in neurons from subcortical networks but are mainly detected in separate neurons in the 
forebrain. Also, co-immunoprecipitation experiments indicated physical proximity in the hippocampus, a 
prerequisite to mu-delta heteromerization. Altogether, data suggest that mu-delta functional interactions take 
place at systems level for high-order emotional and cognitive processing whereas mu-delta may interact at 
cellular level in brain networks essential for survival, which has potential implications for innovative drug design 
in pain control, drug addiction and eating disorders. 
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The opioid system acts as a major key player in reward 
and motivation but also regulates emotional responses and 
cognition. In addition, this neuromodulatory system 
impacts on nociception, and autonomic functions [1]. The 
three opioid receptors mu, delta and kappa are homologous 
G protein coupled receptors (GPCRs) [2] and both opioid 
receptors and endogenous opioid peptides are largely 
expressed throughout the nervous system [3]. Interestingly, 
several decades of opioid pharmacology have brought to 
light the complexity of the opioid physiology, which 
initiated extensive studies to determine the respective 
involvement of mu, delta and kappa receptors in pain 
control, drug abuse and mood disorders [4-7]. In particular, 
analyzing the effects of opioid drugs in vivo has revealed 
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functional interactions mainly documented for mu and 
delta [8]. However, whether in vivo receptor interactions 
occur at circuit, cellular or molecular level remains highly 
debated. 
Numerous reports described heteromer formation 
taking place in transfected cells between mu, delta and 
kappa opioid receptors or between one of them and a non-
opioid receptor [9, 10]. As a result, physical interaction 
between two receptors would give rise to a novel 
molecular entity with specific signaling and/or trafficking 
properties. Such heteromers would represent the molecular 
determinant that underlies the integrated changes observed 
at system level. However, mu-delta in vivo co-expression 
and heteromerization remain extremely difficult to tackle 
with existing tools [11]. In vivo co-localization has indeed 
only been reported in dorsal root ganglia (DRG) [12-14], 
spinal cord [15] and within a limited number of brain areas 
[16-18] but, as for most GPCRs, we still miss in-depth 
anatomical mapping of opioid receptors in the brain that 
also provides subcellular resolution.  
We recently addressed in vivo mu-delta co-localization 
using a double mutant line (delta-eGFP/mu-mcherry) that 
expresses functional fluorescent forms of mu and delta 
receptors [19]. This mouse line was obtained by breeding 
delta-eGFP knock-in mice that express a functional delta 
receptor with a fused C-terminal eGFP instead of the 
native receptor [20] with a second knock-in mouse line that 
was generated according to a similar strategy and 
expresses a functional mu receptor with a fused C-terminal 
red fluorescent mcherry protein. The single mutant mice 
showed no detectable alteration of behavior and responses 
to drugs. Mu-mcherry and delta-eGFP fluorescent signals 
were mapped in the nervous system with subcellular 
resolution. We collected fluorescent images of coronal and 
sagittal sections to generate a virtual atlas that can be freely 
searched at http://mordor.ics-mci.fr/. In the double mutant 
mouse line, mu-mcherry and delta-eGFP distributions 
were consistent with previously published data. This 
designates the double fluorescent knock-in mouse as a 
particularly well-suited tool to map mu and delta receptor 
neuronal co-localization throughout the brain. In addition, 
co-immunoprecipitation experiments uncovered mu-delta 
close physical vicinity in the hippocampus and hence 
qualifies the use of the double knock-in animals to address 
the physiopathological relevance of mu-delta 
heteromerization in vivo.  
Co-localization of mu-mcherry and delta-eGFP was 
observed in discrete populations of the DRGs similarly to 
previous reports[12-14] but also across all layers of the spinal 
cord in agreement with a previous study reporting physical 
mu-delta interaction in the spinal cord using co-
immunoprecipitation experiments [15]. In the brain, mu-
delta co-expression was predominantly observed in the 
hippocampus, the hypothalamus, the lateral parabrachial 
nucleus and vestibular nuclei. Additional regions included 
the piriform cortex, the auditory pathway, as well as mid- 
and hindbrain regions involved in the control of movement 
and posture or relaying somatosensory or motor 
information to the autonomic nervous system. 
Surprisingly, mu-delta co-expressing neurons were 
extremely scarce in the forebrain. The analysis of mu-delta 
co-localization in the brain raised interrogations about the 
possible in vivo roles of neuronal co-expression. First, the 
low mu-delta co-expression in forebrain networks 
responsible for higher-order processing was unexpected 
and suggests that, under basal conditions, functional 
interactions between mu and delta take predominantly 
place at circuitry level as far as mood control, reward 
processing and cognition are concerned. Intriguingly, mu-
delta neuronal co-expression is observed in the CA1 area 
of the hippocampus, the piriform cortex and the nucleus of 
the trapezoid body. These regions operate as coincidence 
detector for spatial, olfactive and auditive cues 
respectively [21-23] suggesting critical mu-delta modulation 
of their processing. Mu-delta neuronal co-expression in 
brain areas involved in motor activity also came as a 
surprise and expands our current knowledge of opioid 
physiology. Mu-delta co-localization is indeed present in 
brain areas where it may exert a modulatory role on 
mandibular movements involved in masticatory reflexes 
and jaw movements associated with feeding [24]. In 
addition, mu-delta co-localization is also detected in brain 
areas involved in motor responses that can be correlated to 
the search for food and water, the sexual attraction or the 
avoidance of aversive stimuli. Indeed, the physiological 
impact of mu-delta neuronal co-expression seems related 
to the modulation of both ascending somatosensory 
information and corresponding descending reflex 
responses intended to protect the individual. Neuronal co-
expression of mu and delta receptors is mainly observed in 
subcortical networks responding to presentation of 
noxious or non-noxious aversive stimuli [25, 26] as well as 
in brainstem nuclei tightly connected with the autonomic 
nervous system. Neurons co-expressing mu and delta 
receptors are also distributed within neuronal circuits 
processing food intake, NaCl and water uptake or 
regulating sexual activity [27-29]. Mu-delta crosstalk at 
cellular level may therefore operate in neural circuits 
involved in behaviors associated with body homeostasis 
and sexual activities.  
Neuronal co-expression in brainstem nuclei also 
suggests that the two receptors may functionally contribute 
to several pathological conditions such as drug addiction 
by contributing to somatic and autonomic symptoms 
associated with drug withdrawal. Targeting mu-delta 
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heteromers may therefore constitute a promising and 
entirely novel approach to reduce opioid withdrawal, and 
possibly withdrawal signs associated with other drugs of 
abuse [30]. On the other hand, the high level of co-
localization of mu and delta in neurons in nociceptive 
pathways designates mu-delta heteromers as an attractive 
target in pain management. This view is supported by 
recent data indicating that mu-delta activation with a 
biased agonist induces less tolerance [31]. Also, neuronal 
co-expression of the two receptors in orexin-positive 
neurons of the lateral hypothalamus critically involved in 
both food and drug reward [32], points to mu-delta 
heteromers as potential target for novel strategies to treat 
obesity or to reduce drug-seeking behaviors. 
Overall, our data suggest that mu and delta receptors 
may cooperate intracellularly in neural networks essential 
for survival. Therefore, mu-delta heteromers distributed 
within neural networks associated with abnormal 
nociception, aversive aspects of drug withdrawal or eating 
disorders emerge as very appealing targets for drug design. 
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